LOS ANGELES, March 7 (Reuters) - The U.S. Food and Drug Administration has approved Spectrum Pharmaceuticals Inc's (SPPI.O: Quote, Profile, Research) Levoleucovorin as a treatment for osteosarcoma, a type of bone cancer, the company said on Friday.
Spectrum said it plans to launch sales of the injectable drug by June. (Reporting by Deena Beasley)
© Thomson Reuters 2008 All rights reserved.
uk.reuters.com
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Reuters in Second Life |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Sri Lankan elephant chases rescuers